Background: Multi_potent cells called mesenchymal stem cells )MSCs(, are being investigated in clinical settings as a potential new treatments for various immunological disorders. Methods: Indexed publications in Medline Pub_Med, Web of Science, and Google_Scholar databases were used to perform a review. Results: They have recently been demonstrated to affect endogenous tissues, and immune cells, after first being heralded as a therapeutic option for structural tissue repair. Mesenchymal stem cells, can differentiate into non_mesenchymal cells like-neurons, or epithelial cells as well as tissues. Moreover, mesenchymal stem cells have immunosuppressive qualities independent of human leukocyte antigens )HLA(. It is especially employed to treat graft versus host disease because of its immunosuppressive qualities. An overview of clinical research on the therapeutic benefits of mesenchymal_stem cells is given in this review. It also emphasizes how MSCs are used in clinical trials to treat cardiovascular disease, and graft versus host disease. MSC biological characteristics are largely responsible for their clinical use; they can be injected intravenously to reach inflammatory sites following tissue damage; they can be differentiated into different cells types, they secrete a variety of biomolecules that can promote the healing of damaged cells, and reduce inflammation; and have immunomodulatory capabilities. Conclusions: These cells can either enhance or improve disease in a pathological milieu. Moreover, mesenchymal-stem-cell therapy, and the course of disease may be positively or negatively impacted by changes to this microenvironment.
